Second Interest Only Extension Conditions means satisfaction of each of the following events: (a) no Default or Event of Default shall have occurred and be continuing; (b) satisfaction of all of the First Interest Only Extension Conditions on or prior to June 30, 2018, and (c) confirmation by Agent and Lender that either (i) the Term C Loan Advance has been made on or prior to June 30, 2018, or (ii) the Third Milestone Event has occurred on or prior to September 30, 2018.
Second Interest Only Extension Conditions means satisfaction of each of the following: (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have maintained compliance with Section 7.14 at all times, subject to verification by Collateral Agent and each Lender (including supporting documentation reasonably requested by Collateral Agent or any Lender); (c) as of May 31, 2019, Qualified Cash is at least Seventy-Nine Million Dollars ($79,000,000.00) plus the Qualified Cash A/P Amount; (d) on or before July 31, 2019, Borrower has furnished Collateral Agent and each Lender with (i) FDA minutes of Borrower’s Type C meetings with the FDA, (ii) a study report on the completed formative human factors study required for FUROSCIX® (the “Human Factor Study”), (iii) a copy of the protocol for the summative Human Factors Study submitted to the FDA for comments, and (iv) evidence that the FDA does not require additional human clinical trials prior to a Class 2 resubmission of a new drug application for FUROSCIX®, in each case, in form and substance satisfactory to Collateral Agent and each Lender; and (e) achievement of the First Interest Only Extension Conditions.
Second Interest Only Extension Conditions means satisfaction of each of the following events: (a) no default or Event of Default shall have occurred and be continuing; (b) the First Interest Only Extension Conditions have been satisfied, and (c) either of Performance Milestone III or Performance Milestone IV has been achieved on or prior to June 15, 2025.
Examples of Second Interest Only Extension Conditions in a sentence
On the earlier of Maturity Date and such other date as the Advances otherwise become due and payable, Borrower shall pay a final payment fee (the “Final Payment Fee”) equal to 13% of the Committed Amount, provided however such fee shall increase to 14% of the Committed Amount if the Second Interest Only Extension Conditions are satisfied.
More Definitions of Second Interest Only Extension Conditions
Second Interest Only Extension Conditions means satisfaction of each of the following events: (a) no default or Event of Default shall have occurred, and (b) Borrower achieves Performance Milestone II, subject to verification by Agent (including supporting documentation requested by Agent).
Second Interest Only Extension Conditions means satisfaction of each of the following events: (a) no default or Event of Default shall have occurred and be continuing; (b) the AXS-05 Milestone has been achieved; and (c) the AXS-07 Milestone has been achieved on or prior to April 30, 2026.
Second Interest Only Extension Conditions means satisfaction of each of the following: (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have maintained compliance with Section 7.14 at all times, subject to verification by Collateral Agent and each Lender (including supporting documentation reasonably requested by Collateral Agent or any Lender); (c) as of May 31, 2019, Qualified Cash is at least Seventy-Nine Million Dollars ($79,000,000.00) plus the Qualified Cash A/P Amount; (d) on or before July 31, 2019, Borrower has furnished Collateral Agent and each Lender with (i) FDA minutes of Borrower’s Type C meetings with the FDA, (ii) a study report on the completed formative human factors study
Second Interest Only Extension Conditions means satisfaction of each of the following: (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have maintained compliance with Section 7.14 at all times, subject to verification by Collateral Agent and each Lender (including supporting documentation reasonably requested by Collateral Agent or any Lender); (c) on or before May 15, 2019, Borrower has furnished Collateral Agent and each Lender with (i) FDA minutes of Borrower’s Type C meetings with the FDA evidencing agreement regarding protocols for a dose delivery validation study, (ii) written response from the FDA evidencing agreement regarding protocols for the human factors studies (collectively, the “Dose Delivery Validation and Human Factors Studies”) required for FUROSCIX® and (iii) evidence that the FDA does not require additional clinical trials prior to resubmission of the new drug application for FUROSCIX®, in each case, in form and substance satisfactory to Collateral Agent and each Lender; (d) as of May 31, 2019, Qualified Cash is at least Seventy-Two Million Dollars ($72,000,000.00) plus the Qualified Cash A/P Amount; and (e) achievement of the First Interest Only Extension Conditions.
Second Interest Only Extension Conditions is satisfied except under clause (d)(iv) therein, then August 1, 2019 and (ii) if each condition in the definition of “Third Interest Only Extension Conditions” is satisfied except under clause (d) therein, then October 1, 2019.
Second Interest Only Extension Conditions means satisfaction of each of the following: (a) no Default or Event of Default shall have occurred and be continuing; (b) after the Effective Date, the Borrower shall have achieved Equity Event 2; and (c) the Borrower shall have achieved the First Interest Only Extension Conditions.
Second Interest Only Extension Conditions means satisfaction of each of the following: (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have maintained compliance with Section 7.14 at all times, subject to verification by Collateral Agent and each Lender (including supporting documentation reasonably requested by Collateral Agent or any Lender); (c) on or before May 15, 2019, Borrower has furnished Collateral Agent and each Lender with (i) FDA minutes of Borrower’s Type C meetings with the FDA evidencing agreement regarding protocols for a dose delivery validation study,